AZN - AstraZeneca buying Alexion in $39B cash and stock deal

Alexion (ALXN) owners will receive $60 per share in cash and 2.1243 ADS of AstraZeneca (AZN) for each share of Alexion they own. Based on AZN's recent closing price, that implies a deal value of $39B, or $175 per share. That's about a 45% premium to Alexion's close on Friday.Alexion's leading expertise in complement biology will accelerate AstraZeneca's growing presence in immunology, say the companies. The deal is expected to be immediately accretive to core earnings.A conference call is set to begin shortly. Presentation slides are here.Press release is here.

For further details see:

AstraZeneca buying Alexion in $39B cash and stock deal